JP Morgan Week 2025 - Fabrizio Chines
SIFI, an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco for JP Morgan week. But this year the company is working on launching an exciting new therapy for a rare eye disease and is stretching into the US market for their planned launch.
At the conference, editor-in-chief Jonah Comstock met up with SIFI CEO and Chairman Fabrizio Chines to talk about this novel product and some other trends in the eye care space.
SIFI is developing a treatment for acanthamoeba keratitis, a rare infection that impacts people who wear contact lenses, which are actually more commonly used in the US than in Europe. Current treatment involves administering three different eye drops every hour, so patients can’t sleep. SIFI’s new drug boasts an 87% cure rate in trials with only daily dosing.
Chines also opines on the trends in the ophthalmology space, where he’s seeing a lot of interest in cell and gene therapies, and a little less interest in digital therapeutics than in previous years. He discusses why the eye is a good area for exploring new scientific innovations, notes some of SIFI’s plans for the coming year, and talks about what the marketing efforts look like for a novel rare disease treatment.
Watch the video for the full discussion and stay tuned for more video interviews from JPM 2025.
